The signaling of FXR/RXR, hepatic fibrosis, AMPK/NF-κB, T2DM and adipogenesis are interconnected to a regulatory network, and blocking any one of these pathways cannot be effective for the prevention and treatment of NAFLD or NASH. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.